Related Party License Agreement - Additional Information (Details) - USD ($)			1 Months Ended	6 Months Ended
	May 28, 2021	Sep. 18, 2020	Jul. 31, 2020	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Net cash proceeds from financing activities				$ 89,862,000	$ 19,905,000
Amgen Agreement
Related Party Transaction [Line Items]
Contract manufacturing costs				$ 0	2,400,000
Amgen, Inc.
Related Party Transaction [Line Items]
Ownership percentage of outstanding shares of capital stock				11.34%
Amgen, Inc. | Research and Development
Related Party Transaction [Line Items]
Expense in connection with goods provided				$ 0	$ 2,400,000
Amgen, Inc. | Series A Convertible Preferred Stock
Related Party Transaction [Line Items]
Percentage of capital stock to issue temporary equity			25.00%
Proceeds from equity financings			$ 45,000,000.0
Issuance of convertible preference shares	1,963,093	6,928,566
Issuance of convertible preferred stock with fair value	$ 5,100,000	$ 17,500,000
Net cash proceeds from financing activities	$ 45,000,000.0
Amgen, Inc. | Amgen Agreement
Related Party Transaction [Line Items]
Upfront consideration for license arrangement			500,000
Additional maximum consideration for license agreement upon achievement of specified regulatory milestones			80,000,000.0
Maximum aggregate milestone payments upon achievement of specific commercial milestones across all mab products			$ 350,000,000.0